To assess the clinical relevance of targeting the SSP in CRC for radiosensitizing purposes, we first examined mRNA levels of PHGDH, PSAT1 and PSPH in patient-derived data from normal tissues (TCGA Target GTEx) and CRC tumor tissues (TCGA COAD study) using the online Xena Explorer tool. This evidence concerns the gene PSAT1 and neoplasm.